AMS, Hokkaido University’s startup, today announced that its research abstract with Hokkaido University (Control Number: 1272) has been accepted as a Top-Rated Oral Presentation (TROP) within the Scientific Program of the EANM’26. TROP status is reserved for abstracts that receive the highest review scores among submissions, marking a notable distinction at one of the world’s largest nuclear medicine meetings.

The research is led by Dr. Shiro Watanabe of the Department of Nuclear Medicine, Hokkaido University Hospital, the scientific driving force behind AMS’s technology and a central figure in AMS’s identity as a Hokkaido University–certified startup.

EANM’26 will be held on October 17–21, 2026, at the Austria Center Vienna (ACV), Vienna, Austria. The presentation is scheduled as follows:

• Title: Quantitative Analysis of ¹⁷⁷Lu Urinary Excretion in PRRT Using a Novel Automated ¹⁷⁷Lu Removal System: Correlation with Tumour Burden and the “Tumour Sink Effect”
• Presentation Number: OP-100
• Session: 306 — Clinical Oncology Track, “Neuroendocrine Imaging”
• Date / Time: Sunday, October 18, 2026, 10:05–10:15 AM (within the 9:45–11:15 AM session)
• Hall: Hall C

Quotes
“To have this work selected as a Top-Rated Oral Presentation at EANM’26 is a significant recognition from the international nuclear medicine community,” said Dr. Shiro Watanabe of the Department of Nuclear Medicine, Hokkaido University Hospital, who leads the research. “The ¹⁷⁷Lu recovered from patient urine — captured in the course of routine radioactive-waste processing — was analysed in this study and showed a relationship with tumour burden and the tumour sink effect. We present this purely as a research observation, with the hope that it encourages further scientific investigation.”

"We are pleased that data collected in the course of waste processing has also proved scientifically interesting — although our system is, and remains, an environmental device, not a medical device," said Yuichiro Sugawara, Founder and CEO of AMS. "Its purpose is to make radionuclide therapy cleaner and safer for medical facilities and the surrounding environment, and our mission is to support the safe and sustainable growth of radionuclide therapy."

About AMS
AMS develops innovative solutions that support the safe and sustainable growth of radiopharmaceutical therapies. The company’s flagship system, BSX, helps healthcare providers manage radioactive waste generated during radionuclide therapies, enabling broader adoption of life-changing treatments while enhancing operational efficiency and environmental responsibility.
For more information, please visit:https://www.ams-plan.com/

Important note on BSX
BSX is an environmental device for the treatment and volume reduction of radioactive wastewater (patient urine) at medical facilities. It is not a medical device and has not been approved, cleared, or certified as a medical device by any regulatory authority. The research findings referenced in this release are presented for scientific purposes only and do not constitute any medical, clinical, or diagnostic claim regarding BSX or any other AMS product.